- Company
- Kwangdong wins patent lawsuit against Ibrance in reverse
- by Kim, Jin-Gu Jun 7, 2023 05:38am
- As Kwangdong Pharmaceutical succeeded in reversing the second trial of the patent lawsuit against Ibrance, it boarded the last train for generic exclusivity. As a result, Ibrance's generic for exclusivity is owned by three companies, including Daewoong Pharmaceutical and Shinpoong Pharmaceutical, which won in the first trial, and Kwangdong P
- Company
- Sales of anti-cancer drug 'Taxol' increases by 53%
- by Kim, Jin-Gu Jun 7, 2023 05:38am
- Sales of the original Paclitaxel anti-cancer drug 'Taxol' increased 53% in one year. This change has seemed to have occurred as Boryung took over domestic sales from the beginning of this year. According to IQVIA, a pharmaceutical market research institute, on the 2nd, Taxol's sales in the first quarter was KRW 2.9 billion. This is a 53
- Company
- Pfizer's ADC Mylotarg can be prescribed by Big 5
- by Eo, Yun-Ho Jun 7, 2023 05:38am
- Pfizer's new ADC drug, Mylotarg, has settled in a Big 5 general hospital. According to the related industry, Pfizer Korea's acute myeloid leukemia (AML) Mylotarg is a drug for medical institutions such as SMC, SNUH, Seoul St. Mary's Hospital, AMC, Shinchon Severance Hospital, as well as advanced general hospitals such as the National Cancer
- Company
- 'Saxenda' continues to dominate weight-loss market
- by Kim, Jin-Gu Jun 7, 2023 05:38am
- 'Saxenda (Liraglutide)' is further strengthening its dominance in the obesity treatment market. In the first quarter, it recorded sales of KRW 15.9 billion, 53% increase from the previous year, more than doubling the gap with the runner-up product, 'Qsymia (Phentermine+Topiramate).' However, it remains to be seen how much longer Saxenda'
- Policy
- Voluntary price reduction of Diacomit/Olpadine up to↓40%
- by Lee, Hye-Kyung Jun 5, 2023 05:37am
- The drug prices of Diacomit, a treatment for Dravet syndrome, and Olpadine, a treatment for hereditary tyrosinemia, which is a rare essential drug, fell by up to 40%. The KOEDC said in a press release on the 1st, “In the case of Diacomit and Olpadine, insurance prices were voluntarily reduced on April 1 and May 1, respectively.” As a resu
- Policy
- Evrysdi, a tx for Roche's spinal muscular dystrophy, passed
- by Lee, Hye-Kyung Jun 5, 2023 05:37am
- Roche Korea's oral 5q spinal muscular atrophy treatment Evrysdi Dry Syrup has been recognized for its benefits and has crossed the insurance threshold. The HIRA released the results of the '2023 6th Pharmaceutical Reimbursement Evaluation Committee' deliberation on the 1st. Ace Pharma's Megval 50mg and H.I.Pharm's Melpspal 50mg, both of which a
- Policy
- Non-face-to-face demonstration will be alternative relief ?
- by Lee, Jeong-Hwan Jun 5, 2023 05:37am
- While the non-face-to-face treatment pilot project started on the 1st, it is attracting attention that the government will "seek ways to use substitute drugs" as a way to prevent inconvenience caused by the lack of prescription drugs at the pharmacy near the patient after treatment. There is a lot of interest in whether the alternative treat
- Company
- Interleukin inhibitors Cosentyx·Tremfya busy extending reim
- by Eo, Yun-Ho Jun 5, 2023 05:37am
- News of reimbursement extensions granted for interleukin inhibitors is continuing in Korea. According to industry sources, the scope of reimbursement for Novartis Korea's IL-17A inhibitor 'Cosentyx UnoReady Pen' 300mg/2mL, and Janssen Korea's IL-23 inhibitor ‘Tremfya (guselkumab)' have been extended since last month, and the 1st of this
- Opinion
- [Reporter’s View]Rise of adjuvant therapies amid concerns
- by Eo, Yun-Ho Jun 5, 2023 05:37am
- Although it may not be the same, the concept of administering a drug for ‘prevention’ has been around for a while. Patients who have chronic diseases have been taking drugs to ‘manage’ their condition rather than treat it. Also, some drugs just exist to prevent a condition, like anticoagulants. The same has just recently been appli
- Policy
- The method of revaluation of wages that Godex has changed
- by Lee, Tak-Sun Jun 5, 2023 05:36am
- It is noteworthy whether HIRA will act as a variable by changing the evaluation method starting with the re-evaluation of benefit adequacy this year. The improved evaluation method is to increase the objectivity of the social demand part, which is the third evaluation item. Accordingly, in the case of drugs whose clinical usefulness is uncle
